Pharma news
Pharma
Germany-based CureVac has accused BioNTech of infringing four patents related to messenger ribonucleic acid technology. 7 July 2022
Americas
Licensing partners aim to prevent the introduction of a proposed eye drop generic treatment before the expiration of four patents. 5 July 2022
Pharma
The ruling marks the latest development of a long-running dispute over the alleged delay of a generic version of the blockbuster painkiller. 5 July 2022
Pharma
The UK Supreme Court ruling involving Pfizer and Flynn is important for any company considering an appeal against the regulator, say Sophie Lawrance and James Batsford of Bristows. 30 June 2022
Pharma
Bristol-Myers Squibb claims violations under the Hatch-Waxman Act in an attempt to shut down generic. 30 June 2022
Pharma
Justice Mellor was unconvinced by arguments that Teva could have cleared the way. 30 June 2022
Pharma
Pfizer is facing a lawsuit centring on its COVID-19 antiviral, Paxlovid, after Enanta Pharmaceuticals filed a complaint citing patent infringement. 28 June 2022
Pharma
India-based Dr Reddy’s has ended its litigation with Indivior and Aquestive Therapeutics over a generic version of opioid addiction treatment Suboxone sublingual film. 27 June 2022
Pharma
The director of the US Patent and Trademark Office, Kathi Vidal, has unveiled long-anticipated guidance for the procedures governing the discretionary denials that can be handed down by the US Patent Trial and Appeal Board (PTAB) when declining to review a patent’s validity. 23 June 2022
Pharma
The US Court of Appeals for the Federal Circuit has held that a patent covering Novartis’ multiple sclerosis drug Gilenya is invalid, potentially opening the floodgates for the introduction of generic versions of the drug. 23 June 2022